Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The program taps into several OpenAI models and can be used across a wide range of therapeutic indications. Both Big Pharma ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Sanofi, a leading global healthcare company, has received the “Corporate Social Impact Award 2024 – Gold level” for the fifth ...